TheEdgeResearch
Home / Stocks / DGEN

Deltagen Inc. (DGEN)

OTC Healthcare Biotechnology
$0.00 ▲ +0.00%
Market Cap
$3,859
Sector
Healthcare
Industry
Biotechnology
Beta
2.49
52-Wk Range
0.0001-0.0001
CEO
Robert J. Driscoll
Country
US
Currency
USD

Deltagen Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in San Mateo, CA, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $3,859. On trailing twelve-month figures it carries a trailing P/E of 0.04, a net margin of 28.9%. Its beta of 2.49 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
0.04
Price / Sales
0.01
Price / Book
0.00
EV / EBITDA
0.37
Gross margin
29.3%
Operating margin
29.3%
Net margin
28.9%
Return on equity
Debt / equity
0.01
Current ratio
2.30
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
0
IPO date
2000-08-03
Headquarters
San Mateo, CA, US
About Deltagen Inc.

Deltagen Inc. provides drug discovery tools and services to the biopharmaceutical industry. The company offers a suite of programs designed to enhance the efficiency of drug discovery, including access to biological models, as well as small-molecule and secreted protein drug targets. It also provides target validation data in the areas of immunology and metabolic diseases. The company was incorporated in 1999 and is headquartered in San Mateo, California.

Comparable companies

Deltagen Inc. is most often compared with the following Healthcare names:

CVHIFCYPSNMRDNMXSQMDTREMITHCTTNGNQUPHWEQL
More research on DGEN
DGEN technical analysis DGEN TheEdge Score Compare against peers
Open full interactive analysis & DCF →